Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing
Cancer Medicine · 2025-10 · 14 (19)
DOI: 10.1002/cam4.71231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 26.09.2025. Verfasst von Gemma Caliendo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical and Molecular Pathology, AOU University of Campania "Luigi Vanvitelli", Napoli, Italy. Hauptthemen laut MEDLINE: DNA Glycosylases, Breast Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The MUTYH gene is involved in DNA repair and is known for MAP ( MUTYH ‐associated polyposis), an autosomal recessive disorder that predisposes individuals to colorectal cancer (CRC), with a lifetime risk ranging from 40% to 90%. Homozygosity or double heterozygosity (DH) for pathogenic variants (PVs) in MUTYH causes MAP, but several studies suggest that monoallelic PVs may also increase cancer risk, mainly CRC and breast cancer (BC).
Methods
We analyzed MUTYH status in a cohort of 130 patients referred to our familial cancer clinic for suspected hereditary cancer, describing their mutations and clinical features, and comparing the MUTYH mutation rate between our cancer cohort and a group of 150 healthy volunteers. We also described the genetic profile and clinical features of probands relatives, when possible.
Results
10% of our cancer patients carried a MUTYH PV, while the gene was wild type in all the samples from the control group. The most frequent PVs were c.1187G>A (p.Gly396Asp) and c.536A>G (p.Tyr179cys). We found a double mutation (DM) in 6 patients, with one carrying a DM in MUTYH and the other 5 harboring mutations in MUTYH and other cancer susceptibility genes ( CHEK2, BRIP1, MLH1 , and BRCA1 ).
Conclusions
The higher MUTYH mutation rate observed in the cancer cohort compared with the control group; cancer recurrence observed in the heterozygous carriers and in both maternal and paternal family branches of patients harboring a DM suggests that MUTYH PVs may play a role in cancer predisposition and progression, even when monoallelic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Clinical and Molecular Pathology, AOU University of Campania "Luigi Vanvitelli", Napoli, Italy.
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
- Oncology Unit, Vallo Della Lucania-Agropoli Hospital, Salerno, Italy.
ORCID-Profile: Chiara Della Pepa
Zitieren
APA
Caliendo, G., Della Pepa, C., Mignano, A., Albanese, L., Passariello, L., Cozzolino, A., Iengo, F., Molinari, A. M., Pesce, L., & Vietri, M. T. (2025). Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing. Cancer Medicine, 14(19). https://doi.org/10.1002/cam4.71231
Vancouver
Caliendo G, Della Pepa C, Mignano A, Albanese L, Passariello L, Cozzolino A, et al. Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing. Cancer Medicine. 2025;14(19). doi:10.1002/cam4.71231
BibTeX
@article{Caliendo2025,
author = {Caliendo, Gemma and Della Pepa, Chiara and Mignano, Alessia and Albanese, Luisa and Passariello, Luana and Cozzolino, Anna and Iengo, Francesca and Molinari, Anna Maria and Pesce, Laura and Vietri, Maria Teresa},
title = {Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {19},
doi = {10.1002/cam4.71231}
}
EUVIMED